What is the Haemonetics Corporation stock price forecast?

Haemonetics Corporation is currently trading at $74.43. View real-time AI analysis on Alpha Lenz.

What is Haemonetics Corporation insider trading activity?

View the latest insider trading data for Haemonetics Corporation on Alpha Lenz.

What is Haemonetics Corporation's P/E ratio?

Haemonetics Corporation's P/E ratio is 22.3.

Haemonetics Corporation

NYSE · HAE

$74.43-2.48(-3.22%)Pre-market

Ask about Haemonetics Corporation's future dividend policy...

Alpha Chat Insight

“Haemonetics Corporation trades at a P/E of 22.3 (fair value) with strong ROE of 18.8%. 3Y revenue CAGR of 11.1% highlights clear growth momentum.”

Ask for details →

Company Overview

Haemonetics Corporation is a global healthcare company dedicated to providing innovative blood management solutions for organizations around the world. The company plays a crucial role in the healthcare industry by offering devices and services that aim to improve the quality, efficiency, and safety of blood supply. Haemonetics is known for its comprehensive portfolio, which includes blood collection and processing systems, plasma collection devices, and software solutions for blood centers and hospitals. The core focus of Haemonetics' offerings lies in enhancing blood donor and patient care, optimizing blood banks' operations, and ensuring the safety and availability of blood and blood components. It serves a wide array of sectors, including hospitals, blood centers, and plasma collection centers, facilitating the global demand for transfusion medicine. With its headquarters in Boston, Massachusetts, Haemonetics continues to influence the landscape of healthcare through its commitment to innovation and its significant contributions to enhancing blood management practices. By catering to a vital segment of the healthcare system, Haemonetics Corporation supports the delivery of essential medical treatments and therapies worldwide.

CEOMr. Christopher A. Simon

Websitehttps://www.haemonetics.com

SectorHealthcare

IndustryMedical Devices

Employees3,657

Company Statistics

FY 2025

Profile

$3.75BMarket Cap

$1.36BRevenue

0.00Shares Out

3,657Employees

Margins

55.04%Gross

23.28%EBITDA

14.78%Operating

15.58%Pre-Tax

12.32%Net

Valuation

22.34P/E

4.56P/B

2.75EV/Sales

14.72EV/EBITDA

26.30P/FCF

Growth (CAGR)

11.07%Rev 3Yr

6.60%Rev 5Yr

41.41%Op Inc 3Yr

6.64%Op Inc 5Yr

56.94%Net Inc 3Yr

16.99%Net Inc 5Yr

Returns

7.22%ROA

18.83%ROE

9.55%ROIC

Financial Health

$306.76MCash & Cash Equivalents

$1.32BNet Debt

198.59%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Haemonetics Corporation trades at a P/E of 22.3 (fair value) with strong ROE of 18.8%. 3Y revenue CAGR of 11.1% highlights clear growth momentum.”

Ask for details →

Frequently Asked Questions

Haemonetics Corporation (ticker: HAE) is a company listed on NYSE in the Healthcare sector (Medical Devices). It has approximately 3,657 employees. Market cap is $3.7B.

The current price is $74.43 with a P/E ratio of 22.34x and P/B of 4.56x.

ROE is 18.83% and operating margin is 14.78%. Annual revenue is $1.4B.